Regeneron's Oncology R&D Boosted With MedImmune's ADC Expertise
This article was originally published in Scrip
Executive Summary
US biotech Regeneron Pharmaceuticals Inc. has licensed rights to the use of MedImmune's "warhead and linker" technology for developing antibody-drug conjugates (ADCs) against a number of undisclosed cancer targets, the companies announced April 5.